Clay Thorp - 15 Dec 2022 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact for Clay Thorp
Issuer symbol
CLSD
Transactions as of
15 Dec 2022
Transactions value $
$0
Form type
4
Filing time
19 Dec 2022, 18:41:09 UTC
Previous filing
24 Jun 2022
Next filing
21 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLSD Common Stock Other $0 -1.41M -28.41% $0.00 3.55M 15 Dec 2022 See footnote F1, F2, F3
transaction CLSD Common Stock Other $0 +8.52K +106.53% $0.00 16.5K 15 Dec 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a pro rata distribution, and not a purchase or sale of securities, by Hatteras Venture Partners III, LP ("HVP III") and Hatteras Venture Affiliates III, LP ("HVA III") to its general partners and limited partners without additional consideration.
F2 The Reporting Person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
F3 The Reporting Person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.